Pivotal-Point Follow-Up QuidelOrtho (QDEL): Strategic Sale of the Point-of-Care Division Triggers Massive Price Surge

QuidelOrtho is a global leader in the field of in-vitro diagnostics, developing advanced test solutions for laboratories and medical practices. On June 29, the stock soared over 32%. The trigger for this surge was reports that the company is considering selling its Point-of-Care testing division for approximately $1.5 billion to private equity firms such as Advent International. This move fundamentally benefits the company, as the proceeds could drastically reduce its high debt burden of $3.8 billion resulting from the Ortho merger in 2022. The...